The Effect of Microbiome-Modulating Therapeutics on Anthropometric and Hemodynamic Biomarkers in Metabolic Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression of Clinical Trials.
Pradipta Paul, Iman Dajani, Ridhima Kaul, Ali Chaari
{"title":"The Effect of Microbiome-Modulating Therapeutics on Anthropometric and Hemodynamic Biomarkers in Metabolic Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression of Clinical Trials.","authors":"Pradipta Paul, Iman Dajani, Ridhima Kaul, Ali Chaari","doi":"10.1111/obr.70215","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a prevalent cardiometabolic disorder characterized by central obesity, insulin resistance, dyslipidemia, and hypertension. Microbiome-targeted therapies with probiotics, prebiotics, and synbiotics may improve outcomes by modulating metabolism, inflammation, and blood pressure.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) in adults with MetS. Searches through April 2023 identified eligible RCTs, yielding 19 studies and 21 independent comparisons. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random effects model. Subgroup analyses and meta-regressions examined moderators and heterogeneity.</p><p><strong>Results: </strong>A total of 19 studies comprising 21 trial comparisons were included. Microbiome-modulating interventions were associated with modest reductions in waist circumference and body weight (BW), indicating improvements in central adiposity. In contrast, effects on body mass index (BMI) were limited, and no meaningful changes were observed in systolic or diastolic blood pressure (DBP). Subgroup and meta-regression analyses suggested that higher microbial dose, longer intervention duration, and greater baseline adiposity were associated with more pronounced anthropometric responses. Moderate heterogeneity was observed across several outcomes.</p><p><strong>Conclusions: </strong>Microbiome-targeted therapies reduced waist circumference (WC) and BW in MetS but had no effect on BMI, systolic blood pressure (SBP), or DBP. These safe interventions may complement lifestyle strategies. Larger, standardized trials with microbiome profiling are needed to refine therapeutic use. These findings support a potential adjunctive role for microbiome-targeted therapies in MetS, particularly for central adiposity, though standardized, longer duration trials with microbiome profiling are needed to clarify clinical utility.</p>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":" ","pages":"e70215"},"PeriodicalIF":7.6000,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/obr.70215","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Metabolic syndrome (MetS) is a prevalent cardiometabolic disorder characterized by central obesity, insulin resistance, dyslipidemia, and hypertension. Microbiome-targeted therapies with probiotics, prebiotics, and synbiotics may improve outcomes by modulating metabolism, inflammation, and blood pressure.
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) in adults with MetS. Searches through April 2023 identified eligible RCTs, yielding 19 studies and 21 independent comparisons. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random effects model. Subgroup analyses and meta-regressions examined moderators and heterogeneity.
Results: A total of 19 studies comprising 21 trial comparisons were included. Microbiome-modulating interventions were associated with modest reductions in waist circumference and body weight (BW), indicating improvements in central adiposity. In contrast, effects on body mass index (BMI) were limited, and no meaningful changes were observed in systolic or diastolic blood pressure (DBP). Subgroup and meta-regression analyses suggested that higher microbial dose, longer intervention duration, and greater baseline adiposity were associated with more pronounced anthropometric responses. Moderate heterogeneity was observed across several outcomes.
Conclusions: Microbiome-targeted therapies reduced waist circumference (WC) and BW in MetS but had no effect on BMI, systolic blood pressure (SBP), or DBP. These safe interventions may complement lifestyle strategies. Larger, standardized trials with microbiome profiling are needed to refine therapeutic use. These findings support a potential adjunctive role for microbiome-targeted therapies in MetS, particularly for central adiposity, though standardized, longer duration trials with microbiome profiling are needed to clarify clinical utility.
期刊介绍：
Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities.
Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field.
The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
